Literature DB >> 35125721

Analysis of the Coagulation Profile in Children with HIV Infection-Effect of Disease and Anti Retroviral Therapy.

Priya Thomas1, Sunita Sharma1, Jagdish Chandra2, Anita Nangia1, Shivali Sehgal3.   

Abstract

The pathogenesis of hypercoagulability in HIV infection is multifactorial and usually more than one factor is responsible for a thromboembolic episode. The present study was conducted to evaluate the effect of HIV infection and antiretroviral therapy on various coagulation parameters in paediatric patients. Forty two newly diagnosed paediatric patients with HIV infection who were enrolled at the Anti-Retro viral Therapy (ART) centre of Kalawati Saran Children's Hospital were included in the study. The patients were grouped into 4 clinical stages according to the WHO clinical staging of HIV disease. Coagulation tests [PT, aPTT, fibrinogen, D-Dimer and coagulation inhibitors i.e. Protein C (PC), Protein S (PS) and antithrombin III (AT III), Lupus anticoagulant (LA) and Anti phospholipid antibody (APLA)] were performed in all the patients at the time of diagnosis and repeated after 6 months. All the patients were started on antiretroviral therapy within 2 months of their diagnosis. At the time of diagnosis, prolonged PT and aPTT were observed in 30.9% and 23% of the cases respectively. Hyperfibinogenemia was seen in 11.9% of patients. D-Dimer was raised in 83.3% of patients. PS, PC & AT activities were reduced in 90.4%, 42.8% & 11.9% of cases respectively. A reduction in the PC and AT activity was seen from clinical stage 1 to 4, but the change was not statistically significant. On follow up after 6 months, a statistically significant reduction in the level of fibrinogen and D-Dimer was seen. Even though there was improvement in the activity of all the coagulation inhibitor after 6 months, statistically significant improvement was seen only for PS. The current study shows that HIV produces a hypercoagulable state in children. Raised d-dimer level and deficiency of natural anticoagulants contribute to the thrombophilic state. © Indian Society of Hematology and Blood Transfusion 2021.

Entities:  

Keywords:  Anti-retroviral therapy; Children; Coagulation profile; HIV

Year:  2021        PMID: 35125721      PMCID: PMC8804129          DOI: 10.1007/s12288-021-01440-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

Review 1.  Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.

Authors:  Nancy F Crum-Cianflone; Jhamillia Weekes; Mary Bavaro
Journal:  AIDS Patient Care STDS       Date:  2008-10       Impact factor: 5.078

Review 2.  Current update on HIV-associated vascular disease and endothelial dysfunction.

Authors:  Hong Mu; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 3.  Is chronic HIV infection associated with venous thrombotic disease? A systematic review.

Authors:  S K Klein; E J Slim; M D de Kruif; T T Keller; H ten Cate; E C M van Gorp; D P M Brandjes
Journal:  Neth J Med       Date:  2005-04       Impact factor: 1.422

4.  Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project.

Authors:  P S Sullivan; M S Dworkin; J L Jones; W C Hooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

5.  Antiphospholipid antibodies in HIV-positive patients.

Authors:  Liliana Galrão; Carlos Brites; Maria Luíza Atta; Ajax Atta; Isabella Lima; Fernanda Gonzalez; Fernanda Magalhães; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

6.  Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series.

Authors:  Michael C Jacobson; Bruce J Dezube; David M Aboulafia
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

7.  Effects of first-line anti-retroviral therapy on blood coagulation parameters of HIV-infected patients attending a tertiary hospital at Abuja, Nigeria.

Authors:  I A Nasir; A Owolagba; A E Ahmad; M M Barma; P O Musa Po; M Bakare; Y Ibrahim; D O Amadu
Journal:  Malays J Pathol       Date:  2016-08       Impact factor: 0.656

8.  Acquired protein C and protein S deficiency in HIV-infected patients.

Authors:  Matthias Erbe; Volker Rickerts; Rupert Martin Bauersachs; Edelgard Lindhoff-Last
Journal:  Clin Appl Thromb Hemost       Date:  2003-10       Impact factor: 2.389

9.  Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients.

Authors:  F Bissuel; M Berruyer; X Causse; M Dechavanne; C Trepo
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

10.  Prevalence of antiphospholipid and antiplatelet antibodies in human immunodeficiency virus (HIV)-infected Chilean patients.

Authors:  Iván Palomo; Marcelo Alarcón; Cecilia Sepulveda; Jaime Pereira; Ricardo Espinola; Silvia Pierangeli
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.